iMDx Pushes for In-House Transplant Testing at American Transplant Congress
Event summary
- iMDx to showcase GraftAssure technology at the American Transplant Congress in Boston from June 20–24, 2026.
- Company to announce grant winners for research on economics of in-house transplant testing.
- Third-party poster to present favorable head-to-head data comparing GraftAssureIQ to commercial assays.
- iMDx seeks FDA marketing authorization for GraftAssureDx, aiming to enable local transplant center labs to perform dd-cfDNA testing.
The big picture
iMDx is positioning itself at the forefront of a potential paradigm shift in transplant monitoring, aiming to move testing from centralized labs to local transplant centers. The company's GraftAssure technology could enable faster, more affordable testing, aligning with broader industry trends toward decentralized diagnostics. Success hinges on securing FDA approval and demonstrating the economic viability of in-house testing through upcoming research grants.
What we're watching
- Regulatory Approval
- Whether iMDx can secure FDA marketing authorization for GraftAssureDx, enabling local transplant center labs to perform dd-cfDNA testing.
- Market Adoption
- The pace at which transplant centers adopt in-house testing solutions like GraftAssure, potentially disrupting the centralized lab model.
- Competitive Positioning
- How iMDx differentiates GraftAssure technology against established commercial assays in the transplant monitoring space.
Related topics